Mission Therapeutics Ltd.

Biopharmaceutical venture capital fundraising is on the rise in 2024, boosted in part by surging numbers of $100m-plus mega-rounds, including a pair of large financings that ended June and started Jul

Recent biopharmaceutical venture capital financings reflect a worldly investment view, even at the $100m-plus mega-round level where the largest investments tend to be more frequent in the US. The six

Mission Therapeutics is looking to protein modulation to treat a variety of diseases associated with malfunctioning mitochondria and has raised just over £25m ($32m) to advance its candidates, includ

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning